Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01151423 · ClinicalTrials.gov registry record · Phase 2
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
A Phase 2 study of Acquired Thrombotic Thrombocytopenic Purpura, sponsored by Ablynx, a Sanofi company.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 20
- Study locations
NCT01151423 is a Phase 2 study of Acquired Thrombotic Thrombocytopenic Purpura that has completed, run by Ablynx, a Sanofi company. The registered enrollment target is 75 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT01151423, a Phase 2 study of Acquired Thrombotic Thrombocytopenic Purpura, has completed, sponsored by Ablynx, a Sanofi company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP. Patients received either placebo or anti-vWF Nanobody as adjunctive therapy to plasma exchange (PE).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Caplacizumab
Study Locations (20)
Other
- Investigator Site - Liverpool
- Investigator Site - Melbourne
- Investigator Site - Woolloongabba
- Investigator Site - Graz
- Investigator Site - Vienna
- Investigator Site - Antwerp
New York
- Investigator Site - New York
- Investigator Site - Rochester
- Investigator Site - Valhalla
North Carolina
- Investigator Site - Durham
- Investigator Site - Winston-Salem
California
- Investigator Site - Los Angeles
District of Columbia
- Investigator Site - Washington D.C.
Georgia
- Investigator Site - Atlanta
Missouri
- Investigator Site - St Louis
Ohio
- Investigator Site - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01151423
The ClinicalTrials.gov registry entry for NCT01151423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ablynx, a Sanofi company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acquired Thrombotic Thrombocytopenic Purpura appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01151423 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01151423 about?
NCT01151423 is a clinical study titled "Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)". This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP. Patients received either placebo or anti-vWF Nanobody as adjunctive therapy to plasma exchange (PE).
What is the current status of trial NCT01151423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2011-01. Estimated completion is 2014-03.
What conditions does trial NCT01151423 study?
This clinical trial studies the following conditions: Acquired Thrombotic Thrombocytopenic Purpura.
What interventions are being tested in trial NCT01151423?
The interventions under investigation include: Placebo (BIOLOGICAL), Caplacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01151423?
This trial is sponsored by Ablynx, a Sanofi company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01151423 being conducted?
This trial has 20 study locations across California, District of Columbia, Georgia, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.